GeoVax Labs, Inc. Warrants - GOVXW STOCK NEWS

Welcome to our dedicated page for GeoVax Labs Warrants news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs Warrants stock.

GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company specializing in developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers.

Utilizing novel proprietary platforms like the modified vaccinia ankara - virus-like particle (MVA-VLP) vaccine platform, GeoVax's pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and gene-directed therapy for head and neck cancers.

Additional research programs focus on preventive vaccines against infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, along with immunotherapies for various solid tumors.

Recent achievements include positive initial safety and immune response findings from a Phase 2 clinical trial evaluating GEO-CM04S1, the COVID-19 vaccine, as a heterologous booster in 63 healthy adults who previously received the Pfizer or Moderna mRNA vaccine. The trial has demonstrated statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants.

11/28/2023 09:00 AM

News

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Rhea-AI Summary

GeoVax Labs, Inc. (GOVX) presented Phase 2 clinical trial data for its next-generation COVID-19 vaccine, GEO-CM04S1, at the World Vaccine Congress, demonstrating potent antibody and cellular immunity in immunocompromised patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.73%

Tags

11/14/2023 09:00 AM

News

Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Rhea-AI Summary

GeoVax Labs, Inc. (Nasdaq: GOVX) presents preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine, at the Vaccines Summit 2023 conference. The data demonstrate single-dose protection against multiple SARS-CoV-2 variants, including the Omicron variant, with a focus on inducing both antibodies and T-cell responses. The company is also evaluating its dual antigen COVID-19 vaccine, GEO-CM04S1, in three Phase 2 clinical trials, targeting immunocompromised patients and healthy individuals who have previously received the Pfizer or Moderna mRNA vaccine.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.73%

Tags

11/08/2023 04:00 PM

News

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary

GeoVax Labs, Inc. (Nasdaq: GOVX) announced significant progress in its Phase 2 Program of GEO-CM04S1, a next-generation COVID-19 vaccine. The company presented safe administration and tumor reduction data for Gedeptin® at the AACR-AHNS Head and Neck Cancer Conference. They also secured a multi-product license for ProBioGen's AGE1.CR.pIX® suspension cell line to enhance manufacturing capabilities. The company will host a conference call and webcast today at 4:30 p.m. ET.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.64%

Tags

10/31/2023 09:00 AM

News

GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023

Rhea-AI Summary

GeoVax Labs, Inc. (Nasdaq: GOVX) will report its third quarter 2023 financial results on November 8, 2023, after the close of U.S. markets. The company will host a live conference call and webcast at 4:30 p.m. ET to provide a corporate update and discuss financial results.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.41%

Tags

10/30/2023 09:00 AM

News

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Rhea-AI Summary

GeoVax Labs has commenced the planned site expansion for the Phase 2 clinical trial of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, in immunocompromised patients. The trial will enroll patients at multiple medical centers across the United States. The Phase 2 trial aims to evaluate the safety and immunogenicity of GEO-CM04S1 compared to Pfizer/BioNTech or Moderna mRNA-based vaccines in patients with hematologic malignancies who have received stem cell transplants or CAR T cell therapy. GeoVax believes that GEO-CM04S1 has the potential to offer a more robust and durable degree of protection for immunocompromised patients and as a booster vaccine for healthy individuals.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.4%

Tags

10/25/2023 09:00 AM

News

GeoVax to Participate in Upcoming November Investor and Industry Events

Rhea-AI Summary

GeoVax Labs, Inc. to participate in four investor and industry events in November

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.12%

Tags

10/24/2023 09:00 AM

News

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

Rhea-AI Summary

GeoVax Labs, Inc. provides an update on key strategic initiatives, including advancements in their COVID-19 vaccine clinical programs and cancer therapy program. They have also received new patents for their vaccines. Initial data readouts from clinical trials are expected soon.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.99%

Tags

10/09/2023 09:00 AM

News

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Rhea-AI Summary

GeoVax Labs receives patent allowance for Marburg virus vaccine, demonstrating 80% survival in nonhuman primate studies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.21%

Tags

10/05/2023 09:00 AM

News

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

Rhea-AI Summary

GeoVax Labs receives Notice of Allowance for patent application on HIV vaccine boost compositions and methods of use.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.56%

Tags

09/27/2023 09:00 AM

News

GeoVax to Participate in Upcoming October Investor and Industry Events

Rhea-AI Summary

GeoVax Labs, Inc. will provide updates on Phase 2 clinical trials for their COVID-19 vaccine and cancer immunotherapy programs. The Chairman and CEO will participate in upcoming investor and industry events, including the Emerging Growth Virtual Conference, BioFuture 2023, and Dawson James Small Cap Growth Conference. A live webcast of the Dawson James presentation will be available on GeoVax's website. One-on-one meetings with management will also be available at the conferences.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of GeoVax Labs Warrants (GOVXW)?

The current stock price of GeoVax Labs Warrants (GOVXW) is $0.1209 as of November 22, 2024.

What is GeoVax Labs, Inc. focused on developing?

GeoVax Labs, Inc. is focused on developing human vaccines and immunotherapies for infectious diseases and solid tumor cancers using innovative proprietary platforms.

What recent achievements has GeoVax Labs, Inc. made?

GeoVax Labs, Inc. achieved positive initial safety and immune response findings in a Phase 2 clinical trial for its COVID-19 vaccine.

Which diseases are targeted by GeoVax's vaccine development programs?

GeoVax targets infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), Zika virus, along with developing immunotherapies for various solid tumors.